FDA Warns Allergan Over Aczone Ad

The FDA’s Division of Drug Marketing, Advertising and Communications has sent Allergan a warning letter concerning an advertisement for the acne drug Aczone that overstated efficacy and omitted important risk information. The Aug. 17 letter says an advertisement for Aczone (dapsone) gel 5 percent is false or misleading. The advertisement is no longer in use and last appeared in May in physician-focused publications, Cathy Taylor, a spokeswoman for Allergan, said.
Washington Drug Letter